FOR RELEASE, June 23, 2008

Trinity Biotech to Demonstrate Destiny Max at MLTD Conference in Athens

DUBLIN, Ireland (June 23rd, 2008)….Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it will demonstrate its new Destiny Max instrument at the MLTD (Mediterranean League against Thromboembolic Diseases) conference in Athens, Greece from June 25th to 28th.

Brendan Farrell, Chief Executive Officer of Trinity Biotech, commented, "We are pleased to demonstrate our new high throughput Destiny Max instrument for the haemostasis market in its final design format at the MLTD conference. The instrument is the result of three years development and will open access for Trinity to the high throughput segment which represents approximately 50% of the overall haemostasis market. The instrument is about to undergo external clinical trials with a view to being formally launched in the European market in quarter four of this year. Combined with our recently rationalized haemostasis reagent product line we believe that we will have a best in class offering for this market upon launch later this year."

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact: Trinity Biotech plc
Ms. Niamh Long
Investor Relations Officer
(353)-1-2769800
niamh.long@trinitybiotech.com

Joe Diaz, Joe Dorame, Robert Blum
Lytham Partners, LLC
(602) 889-9700

END OF RELEASE